Giuseppe Cuttone, Giulio Geraci, Luigi La Via, Nicola Sinatra, Maria Rita Stancanelli, Vincenzo Calabrese
Introduction. Acute Kidney Injury (AKI) is a serious complication in critically ill patients associated with significant morbidity and mortality. Early detection and risk stratification remain challenging, particularly in complex conditions such as septic shock where hemodynamic alterations complicate the clinical picture. Renal Resistive Index (RRI), measured through Doppler ultrasonography, has emerged as a promising non-invasive tool for assessing renal hemodynamics and microcirculatory changes. While various studies have investigated the relationship between RRI and AKI, there has not been a comprehensive systematic evaluation of RRI's utility in predicting and assessing AKI in critical care settings. Objective. The main aim is to evaluate the difference in RRI between patients who manifested AKI and patients who did not manifest AKI. Furthermore, the risk of AKI occurrence related to RRI will be computed. Methods. We will perform systematic research in PubMed and Scopus according to the PRISMA Guidelines. We will screen observational studies, with both retrospective and prospective designs on critically ill patients, without sex or age restriction. Expected results. This systematic review is expected to provide a comprehensive and extensive evaluation of the relationship between RRI and AKI. It will be based on observational studies, as RRI is a risk factor not subject to control by the investigator. In addition to assessing the association between RRI and AKI, the study also aims to highlight potential gaps in current knowledge and suggest directions for future research. Conclusions. The present systematic review protocol will include all existing evidence from published articles evaluating the RRI values in patients manifesting or not AKI.
{"title":"Does the High Renal Resistive Index Reveal an Increased Risk of Acute Kidney Injury? A Protocol for Systematic Review.","authors":"Giuseppe Cuttone, Giulio Geraci, Luigi La Via, Nicola Sinatra, Maria Rita Stancanelli, Vincenzo Calabrese","doi":"10.69097/42-02-2025-02","DOIUrl":"10.69097/42-02-2025-02","url":null,"abstract":"<p><p><b>Introduction.</b> Acute Kidney Injury (AKI) is a serious complication in critically ill patients associated with significant morbidity and mortality. Early detection and risk stratification remain challenging, particularly in complex conditions such as septic shock where hemodynamic alterations complicate the clinical picture. Renal Resistive Index (RRI), measured through Doppler ultrasonography, has emerged as a promising non-invasive tool for assessing renal hemodynamics and microcirculatory changes. While various studies have investigated the relationship between RRI and AKI, there has not been a comprehensive systematic evaluation of RRI's utility in predicting and assessing AKI in critical care settings. <b>Objective.</b> The main aim is to evaluate the difference in RRI between patients who manifested AKI and patients who did not manifest AKI. Furthermore, the risk of AKI occurrence related to RRI will be computed. <b>Methods.</b> We will perform systematic research in PubMed and Scopus according to the PRISMA Guidelines. We will screen observational studies, with both retrospective and prospective designs on critically ill patients, without sex or age restriction. <b>Expected results.</b> This systematic review is expected to provide a comprehensive and extensive evaluation of the relationship between RRI and AKI. It will be based on observational studies, as RRI is a risk factor not subject to control by the investigator. In addition to assessing the association between RRI and AKI, the study also aims to highlight potential gaps in current knowledge and suggest directions for future research. <b>Conclusions.</b> The present systematic review protocol will include all existing evidence from published articles evaluating the RRI values in patients manifesting or not AKI.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fabrizio Cristiano, Guillermo Rosa-Diez, Carlos Guido Musso, Jenny Cristiano
The measurement of glomerular filtration rate (GFR) is essential in diagnosing and managing chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD), both requiring precise renal function assessment. Traditionally, GFR has been estimated using endogenous markers like creatinine and cystatin C, though these can be inaccurate due to factors unrelated to kidney function, such as muscle mass and diet. The iohexol clearance method provides a more accurate and less invasive alternative to traditional markers like inulin or radioactive markers. Iohexol, a non-ionic, water-soluble contrast agent, is exclusively eliminated by glomerular filtration, making it highly suitable for direct GFR estimation. This paper describes procedures for iohexol clearance, involving defined-interval blood samples after intravenous administration. In patients with normal renal function, sampling intervals are more frequent, while in advanced CKD patients, including those with ADPKD, slower iohexol elimination requires wider intervals to ensure accurate clearance analysis. Iohexol has demonstrated high precision and reproducibility, even compared to other markers. Research supports using iohexol to monitor CKD and ADPKD progression effectively. Particularly in ADPKD, iohexol detects subtle but clinically significant GFR changes, even in early disease stages, making it valuable for evaluating targeted therapies. However, iohexol use is limited to specialized centers due to high costs and strict protocols. Its implementation in advanced European healthcare facilities underscores its efficacy, providing reliable GFR estimates that enhance nephrology practice, despite some limitations.
{"title":"Is Iohexol a Possible Method for Estimating Glomerular Filtration Rate?","authors":"Fabrizio Cristiano, Guillermo Rosa-Diez, Carlos Guido Musso, Jenny Cristiano","doi":"10.69097/42-02-2025-03","DOIUrl":"10.69097/42-02-2025-03","url":null,"abstract":"<p><p>The measurement of glomerular filtration rate (GFR) is essential in diagnosing and managing chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD), both requiring precise renal function assessment. Traditionally, GFR has been estimated using endogenous markers like creatinine and cystatin C, though these can be inaccurate due to factors unrelated to kidney function, such as muscle mass and diet. The iohexol clearance method provides a more accurate and less invasive alternative to traditional markers like inulin or radioactive markers. Iohexol, a non-ionic, water-soluble contrast agent, is exclusively eliminated by glomerular filtration, making it highly suitable for direct GFR estimation. This paper describes procedures for iohexol clearance, involving defined-interval blood samples after intravenous administration. In patients with normal renal function, sampling intervals are more frequent, while in advanced CKD patients, including those with ADPKD, slower iohexol elimination requires wider intervals to ensure accurate clearance analysis. Iohexol has demonstrated high precision and reproducibility, even compared to other markers. Research supports using iohexol to monitor CKD and ADPKD progression effectively. Particularly in ADPKD, iohexol detects subtle but clinically significant GFR changes, even in early disease stages, making it valuable for evaluating targeted therapies. However, iohexol use is limited to specialized centers due to high costs and strict protocols. Its implementation in advanced European healthcare facilities underscores its efficacy, providing reliable GFR estimates that enhance nephrology practice, despite some limitations.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kristiana Kola, Martina Catania, Liliana Italia De Rosa, Matteo Brambilla Pisoni, Sara Farinone, Paola Maiucchi, Micaela Petrone, Paolo Manunta, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi
ADPKD is the most common inherited kidney disorder, marked by numerous renal cysts, increased total kidney volume and progressive renal function decline. Mutations in the PKD1 and PKD2 genes, leading to altered cAMP signaling, drive cyst growth. Elevated antidiuretic hormone (ADH) levels further exacerbate cystogenesis. Tolvaptan, a vasopressin V2 receptor antagonist, is the only approved treatment for slowing ADPKD progression, but its use often results in significant polyuria and thirst, affecting patient quality of life. This case report presents a 31-year-old female with ADPKD, classified as Mayo Class 1D, who showed improved tolerance to tolvaptan after co-administering low-dose hydrochlorothiazide (HCT). The patient experienced a significant reduction in polyuria and thirst while maintaining stable kidney function over four years. The annual decline in eGFR was less than expected for her disease class and improved compared to the first year of tolvaptan therapy. This case suggests that HCT may enhance tolvaptan tolerability without reducing its efficacy. Ongoing studies, such as the HYDRO-PROTECT trial, aim to further explore the benefits of combining HCT with tolvaptan in ADPKD management.
{"title":"Boosting Tolvaptan Tolerance in ADPKD: Low-Dose Hydrochlorothiazide Improves Patient Well-being Without Compromising Efficacy - A Case Report.","authors":"Kristiana Kola, Martina Catania, Liliana Italia De Rosa, Matteo Brambilla Pisoni, Sara Farinone, Paola Maiucchi, Micaela Petrone, Paolo Manunta, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi","doi":"10.69097/42-02-2025-06","DOIUrl":"https://doi.org/10.69097/42-02-2025-06","url":null,"abstract":"<p><p>ADPKD is the most common inherited kidney disorder, marked by numerous renal cysts, increased total kidney volume and progressive renal function decline. Mutations in the PKD1 and PKD2 genes, leading to altered cAMP signaling, drive cyst growth. Elevated antidiuretic hormone (ADH) levels further exacerbate cystogenesis. Tolvaptan, a vasopressin V2 receptor antagonist, is the only approved treatment for slowing ADPKD progression, but its use often results in significant polyuria and thirst, affecting patient quality of life. This case report presents a 31-year-old female with ADPKD, classified as Mayo Class 1D, who showed improved tolerance to tolvaptan after co-administering low-dose hydrochlorothiazide (HCT). The patient experienced a significant reduction in polyuria and thirst while maintaining stable kidney function over four years. The annual decline in eGFR was less than expected for her disease class and improved compared to the first year of tolvaptan therapy. This case suggests that HCT may enhance tolvaptan tolerability without reducing its efficacy. Ongoing studies, such as the HYDRO-PROTECT trial, aim to further explore the benefits of combining HCT with tolvaptan in ADPKD management.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yarramachu Dharanidhar Reddy, K Sai Sindhu Singh, Pavuluri Lakshmi Aishwarya, J K Jayaram, Indhumathi Elayaperumal
Background. Acute kidney injury (AKI) is a common and serious complication in patients with decompensated liver disease (DLD), often resulting from ischemic acute tubular necrosis or hepatorenal syndrome. This study examines the role of biochemical markers and ultrasound parameters, such as right atrial pressure, right ventricular hypertrophy, inferior vena cava diameter, hepatic venous flow dynamics, left ventricular diastolic dysfunction, the E/e' ratio, renal peak systolic velocity, renal end-diastolic velocity, and renal resistive index (RI), in predicting AKI severity and outcomes. Methods. A prospective observational study was conducted on 50 DLD patients with AKI, admitted to a tertiary care Hospital. Biochemical parameters including serum creatinine, bilirubin, and albumin along with ultrasound parameters were assessed. AKI was classified according to KDIGO criteria, and renal recovery and mortality were monitored. Diagnostic accuracy was evaluated through ROC analysis. Results. 30% of patients had stage 3 AKI, with 60% of them being male (average age 54 ± 12 years). Stage 3 AKI was a significant predictor of mortality (OR 3.5, p < 0.001), along with renal resistive index (OR 2.8, p = 0.003). ROC analysis showed that serum creatinine and the E/e' ratio, along with the RI, were significant predictors for AKI severity and mortality. Renal recovery occurred in 58%. Conclusion. The simultaneous assessment of clinical, biochemical, and ultrasound parameters enhances the prediction of AKI severity and patient outcomes in DLD. This approach facilitates earlier detection and better management of AKI in this population.
背景。急性肾损伤(AKI)是失代偿性肝病(DLD)患者常见且严重的并发症,通常由缺血性急性肾小管坏死或肝肾综合征引起。本研究探讨生化指标和超声参数的作用,如右心房压、右心室肥厚、下腔静脉直径、肝静脉血流动力学、左心室舒张功能障碍、E/ E比值、肾收缩期峰值速度、肾舒张末期速度和肾阻力指数(RI),在预测AKI严重程度和预后中的作用。方法。一项前瞻性观察研究对50名住院三级医院的DLD合并AKI患者进行了研究。生化参数包括血清肌酐、胆红素和白蛋白以及超声参数进行评估。根据KDIGO标准对AKI进行分类,并监测肾脏恢复和死亡率。通过ROC分析评估诊断准确性。结果:30%的患者为3期AKI,其中60%为男性(平均年龄54±12岁)。3期AKI是死亡率的重要预测因子(OR 3.5, p < 0.001),以及肾抵抗指数(OR 2.8, p = 0.003)。ROC分析显示,血清肌酐和E/ E比值以及RI是AKI严重程度和死亡率的重要预测因子。肾恢复率为58%。结论。同时评估临床、生化和超声参数可以提高对DLD患者AKI严重程度和预后的预测。这种方法有助于在这一人群中更早地发现和更好地管理AKI。
{"title":"Hepatorenal Syndrome - AKI in Decompensated Liver Disease: Clinical Characteristics, Risk Factors, Ultrasound Applications, and Outcomes.","authors":"Yarramachu Dharanidhar Reddy, K Sai Sindhu Singh, Pavuluri Lakshmi Aishwarya, J K Jayaram, Indhumathi Elayaperumal","doi":"10.69097/42-02-2025-11","DOIUrl":"https://doi.org/10.69097/42-02-2025-11","url":null,"abstract":"<p><p><b>Background.</b> Acute kidney injury (AKI) is a common and serious complication in patients with decompensated liver disease (DLD), often resulting from ischemic acute tubular necrosis or hepatorenal syndrome. This study examines the role of biochemical markers and ultrasound parameters, such as right atrial pressure, right ventricular hypertrophy, inferior vena cava diameter, hepatic venous flow dynamics, left ventricular diastolic dysfunction, the E/e' ratio, renal peak systolic velocity, renal end-diastolic velocity, and renal resistive index (RI), in predicting AKI severity and outcomes. <b>Methods.</b> A prospective observational study was conducted on 50 DLD patients with AKI, admitted to a tertiary care Hospital. Biochemical parameters including serum creatinine, bilirubin, and albumin along with ultrasound parameters were assessed. AKI was classified according to KDIGO criteria, and renal recovery and mortality were monitored. Diagnostic accuracy was evaluated through ROC analysis. <b>Results.</b> 30% of patients had stage 3 AKI, with 60% of them being male (average age 54 ± 12 years). Stage 3 AKI was a significant predictor of mortality (OR 3.5, p < 0.001), along with renal resistive index (OR 2.8, p = 0.003). ROC analysis showed that serum creatinine and the E/e' ratio, along with the RI, were significant predictors for AKI severity and mortality. Renal recovery occurred in 58%. <b>Conclusion.</b> The simultaneous assessment of clinical, biochemical, and ultrasound parameters enhances the prediction of AKI severity and patient outcomes in DLD. This approach facilitates earlier detection and better management of AKI in this population.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luca Nardelli, Antonio Scalamogna, Giuseppe Castellano
The success of peritoneal dialysis (PD) relies imperatively on the presence of a safe and well-functioning peritoneal access. The ideal catheter should be easy to position and durable, comfortable and practical to use, have minimal aesthetic impact and present low infectious and mechanical complications. Originally, the catheter that came closest to these characteristics was designed by Tenckhoff at the end of the 1960s. Over the next fifty years, different types of devices were developed with the aim of improving their efficiency and at the same time reducing the associated complications. Overall, none of these catheters has demonstrated a clear superiority over the Tenckhoff catheter and yet up to 30% of PD discontinuations are due to access-related complications. However, nowadays the wide range of existing models bestow the possibility of a personalized choice. This approach, together with the placement technique and the experience of the centre, would allow maximizing the benefits deriving from specific features of the PD catheter in relation to peculiar conditions of the recipient. Therefore, for clinicians involved in the positioning and care of peritoneal access, understanding the principles underlying the different configurations of the PD catheter is necessary to establish a "case by case" approach.
{"title":"[Peritoneal Dialysis Catheter Design: Variants and Clinical Implications].","authors":"Luca Nardelli, Antonio Scalamogna, Giuseppe Castellano","doi":"10.69097/42-02-2025-04","DOIUrl":"https://doi.org/10.69097/42-02-2025-04","url":null,"abstract":"<p><p>The success of peritoneal dialysis (PD) relies imperatively on the presence of a safe and well-functioning peritoneal access. The ideal catheter should be easy to position and durable, comfortable and practical to use, have minimal aesthetic impact and present low infectious and mechanical complications. Originally, the catheter that came closest to these characteristics was designed by Tenckhoff at the end of the 1960s. Over the next fifty years, different types of devices were developed with the aim of improving their efficiency and at the same time reducing the associated complications. Overall, none of these catheters has demonstrated a clear superiority over the Tenckhoff catheter and yet up to 30% of PD discontinuations are due to access-related complications. However, nowadays the wide range of existing models bestow the possibility of a personalized choice. This approach, together with the placement technique and the experience of the centre, would allow maximizing the benefits deriving from specific features of the PD catheter in relation to peculiar conditions of the recipient. Therefore, for clinicians involved in the positioning and care of peritoneal access, understanding the principles underlying the different configurations of the PD catheter is necessary to establish a \"case by case\" approach.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nigel Fernandez-Carlos, Maria L Ocampo, Carlos G Musso, Fabrizio Cristiano, Gustavo Aroca-Martinez, Maria C Giordani
The cloudy bag in peritoneal dialysis is generally associated with infectious peritonitis and non-infectious etiologies. These cloudy bags may have increased cellularity or low/acellular counts. In the case of low cell count, the concomitant detection of fibrin or fat can provide guidance on its etiology. The cloudy peritoneal bag with a whitish appearance is usually due to its high fat content (chyloperitoneum). The etiologies include pharmacological, traumatic or inflammatory causes. The elevated fatty component in chyloperitoneum may be triglycerides (chylous), cholesterol (pseudochylous) or lymph. We present the case of a patient with stage 5 chronic kidney disease (CKD). He starts continuous ambulatory peritoneal dialysis and presents turbid but acellular peritoneal effluent with chylous appearance, negative cultures, and low levels of triglycerides and cholesterol on physicochemical evaluation. It doesn't meet the criteria for chylous or pseudochylous fluid, which is why the term lymphoid fluid is here proposed to describe it, because of its resemblance to lymphatic fluid in color. To our knowledge, this is the first case in the literature to report this effluent (milky-looking fluid without high levels of triglycerides or cholesterol) and to propose a specific term to describe it.
{"title":"Lymphoid Peritoneal Fluid as a Variant of Chylous-Like Effluent in Peritoneal Dialysis: Proposal for a New Diagnostic Term.","authors":"Nigel Fernandez-Carlos, Maria L Ocampo, Carlos G Musso, Fabrizio Cristiano, Gustavo Aroca-Martinez, Maria C Giordani","doi":"10.69097/42-02-2025-09","DOIUrl":"10.69097/42-02-2025-09","url":null,"abstract":"<p><p>The cloudy bag in peritoneal dialysis is generally associated with infectious peritonitis and non-infectious etiologies. These cloudy bags may have increased cellularity or low/acellular counts. In the case of low cell count, the concomitant detection of fibrin or fat can provide guidance on its etiology. The cloudy peritoneal bag with a whitish appearance is usually due to its high fat content (chyloperitoneum). The etiologies include pharmacological, traumatic or inflammatory causes. The elevated fatty component in chyloperitoneum may be triglycerides (chylous), cholesterol (pseudochylous) or lymph. We present the case of a patient with stage 5 chronic kidney disease (CKD). He starts continuous ambulatory peritoneal dialysis and presents turbid but acellular peritoneal effluent with chylous appearance, negative cultures, and low levels of triglycerides and cholesterol on physicochemical evaluation. It doesn't meet the criteria for chylous or pseudochylous fluid, which is why the term lymphoid fluid is here proposed to describe it, because of its resemblance to lymphatic fluid in color. To our knowledge, this is the first case in the literature to report this effluent (milky-looking fluid without high levels of triglycerides or cholesterol) and to propose a specific term to describe it.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Pesce, Domenico Pasculli, Giuseppe Castellano, Luca De Nicola, Giovanni Gambaro, Vincenzo Panichi, Domenico Santoro, Francesca Viazzi, Monica Zanella, Loreto Gesualdo
Background. Effective collaboration between general practitioners (GPs) and nephrologists is crucial for optimizing the management of chronic kidney disease (CKD). The TOSCA-CKD project (Treatment Optimization and Standard of Care Adherence in CKD Primary Care) aimed to evaluate the implementation of guidelines and the use of nephroprotective therapies in primary care. Methods. Clinical data were collected from the medical records of GPs across 12 Italian regions. The data were analyzed at baseline (T0) and after 6 months (T6) of collaboration with nephrologists. During this observational period, GPs were involved in remote education programs, which included expert-led webinars and clinical case-based learning. Results. A total of 76 GPs and 9 nephrologists were involved in the study, evaluating a cohort of 124,759 patients. There was an increase of 23.3% in the uACR test from T0 to T6 (3.0% vs. 3.7%; p < 0.001). Similarly, there was an increase of 15.2% in the use of eGFR from T0 to T6 (29.7% vs. 34.2%; p < 0.001). The rate of CKD diagnosis increased by 17.5% among patients with eGFR < 60 mL/min/1.73 m² (from 4% to 4.7%) and by 40% among patients with ACR > 30 mg/g (from 0.5% to 0.7%). The use of ACEi/ARBs remained stable at approximately 50%, while the treatment with SGLT2i, the new standard of care according to the current CKD guidelines, increased by 29.8% (from 4.7% to 6.1%). Conclusions. The TOSCA-CKD project demonstrated that GPs' remote educational program and a structured co-management approach significantly enhanced the early identification and improved the management of CKD in primary care.
{"title":"Treatment Optimization and Standard of Care Adherence in CKD Primary Care: the TOSCA-CKD project.","authors":"Francesco Pesce, Domenico Pasculli, Giuseppe Castellano, Luca De Nicola, Giovanni Gambaro, Vincenzo Panichi, Domenico Santoro, Francesca Viazzi, Monica Zanella, Loreto Gesualdo","doi":"10.69097/42-02-2025-10","DOIUrl":"https://doi.org/10.69097/42-02-2025-10","url":null,"abstract":"<p><p><b>Background.</b> Effective collaboration between general practitioners (GPs) and nephrologists is crucial for optimizing the management of chronic kidney disease (CKD). The TOSCA-CKD project (Treatment Optimization and Standard of Care Adherence in CKD Primary Care) aimed to evaluate the implementation of guidelines and the use of nephroprotective therapies in primary care. <b>Methods.</b> Clinical data were collected from the medical records of GPs across 12 Italian regions. The data were analyzed at baseline (T0) and after 6 months (T6) of collaboration with nephrologists. During this observational period, GPs were involved in remote education programs, which included expert-led webinars and clinical case-based learning. <b>Results.</b> A total of 76 GPs and 9 nephrologists were involved in the study, evaluating a cohort of 124,759 patients. There was an increase of 23.3% in the uACR test from T0 to T6 (3.0% vs. 3.7%; p < 0.001). Similarly, there was an increase of 15.2% in the use of eGFR from T0 to T6 (29.7% vs. 34.2%; p < 0.001). The rate of CKD diagnosis increased by 17.5% among patients with eGFR < 60 mL/min/1.73 m² (from 4% to 4.7%) and by 40% among patients with ACR > 30 mg/g (from 0.5% to 0.7%). The use of ACEi/ARBs remained stable at approximately 50%, while the treatment with SGLT2i, the new standard of care according to the current CKD guidelines, increased by 29.8% (from 4.7% to 6.1%). <b>Conclusions.</b> The TOSCA-CKD project demonstrated that GPs' remote educational program and a structured co-management approach significantly enhanced the early identification and improved the management of CKD in primary care.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonino Previti, Pietro Manuel Ferraro, Elisa De Tomi, Giovanni Gambaro
Infections related to the peritoneal catheter, whether of the exit-site or of the subcutaneous tunnel (ESI), are a predisposing factor for the development of peritonitis. The regions of Friuli-Venezia Giulia, Trentino-Alto Adige and Veneto (Triveneto) have started a collaborative network to spread knowledge and optimize the use of peritoneal dialysis. The need to collect and aggregate ESI data emerged, therefore the project of a Register of ESIs of the Triveneto (RESIsT) was launched. This work analyzes the preparation and testing phase of the Registry.
{"title":"[Presentation of the Triveneto Exit-Site Infections Register (RESIsT) and Warm-Up of Peritoneal Dialysis Centers].","authors":"Antonino Previti, Pietro Manuel Ferraro, Elisa De Tomi, Giovanni Gambaro","doi":"10.69097/42-02-2025-12","DOIUrl":"https://doi.org/10.69097/42-02-2025-12","url":null,"abstract":"<p><p>Infections related to the peritoneal catheter, whether of the exit-site or of the subcutaneous tunnel (ESI), are a predisposing factor for the development of peritonitis. The regions of Friuli-Venezia Giulia, Trentino-Alto Adige and Veneto (Triveneto) have started a collaborative network to spread knowledge and optimize the use of peritoneal dialysis. The need to collect and aggregate ESI data emerged, therefore the project of a Register of ESIs of the Triveneto (RESIsT) was launched. This work analyzes the preparation and testing phase of the Registry.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sandra La Rosa, Stefania Pesce, Simona Lombardo, Marilena C Fiorino, Antonio Granata
Alport syndrome is a hereditary disorder characterized by hematuria, proteinuria and progressive renal failure, frequently associated with extrarenal manifestations. The pathogenic variants of the COL4A5 gene are associated with X-linked Alport syndrome while those of the COL4A3 and COL4A4 genes are associated with the autosomal recessive (AR) or dominant (AD) form. The disease is characterized by considerable phenotypic variability linked to the different genes involved and the different mutations present, so the symptoms manifest themselves in different frequencies depending on the case. The existence of an autosomal dominant form of Alport syndrome has been identified in recent years thanks to next generation gene sequencing (NGS) techniques which have made it possible to highlight unknown genetic variants of Alport syndrome. The family studied by us presents concomitant heterozygous alterations of the COL4A3 genes (c.1029+5G>A with MAF 0 and c.3211-7A>G with MAF 1:100000), heterozygous alterations of the MTHFR gene (both C677T and A1298C) and homozygous alteration of the PAI-1 gene. While the variant c.3211-7A>G, as shown by genetic databases (ClinVar), appears to be benign, the intronic variant c.1029+5G>A (caused by exon skipping) can be classified as pathogenic due to its characteristics and the fact that it co-segregates with the phenotype within the family. The histological data, in one of the sisters, highlighted the presence of a discrete global glomerular sclerosis and the ultrastructural investigation a thinning of the glomerular basement membrane. New mutational variants of the COL4A3 gene may play a role as risk variants for the development of chronic kidney disease.
{"title":"[New Genetic Variants Involved in the Pathogenesis of Autosomal Dominant Alport Syndrome: A Familial Case Report].","authors":"Sandra La Rosa, Stefania Pesce, Simona Lombardo, Marilena C Fiorino, Antonio Granata","doi":"10.69097/42-02-2025-07","DOIUrl":"10.69097/42-02-2025-07","url":null,"abstract":"<p><p>Alport syndrome is a hereditary disorder characterized by hematuria, proteinuria and progressive renal failure, frequently associated with extrarenal manifestations. The pathogenic variants of the COL4A5 gene are associated with X-linked Alport syndrome while those of the COL4A3 and COL4A4 genes are associated with the autosomal recessive (AR) or dominant (AD) form. The disease is characterized by considerable phenotypic variability linked to the different genes involved and the different mutations present, so the symptoms manifest themselves in different frequencies depending on the case. The existence of an autosomal dominant form of Alport syndrome has been identified in recent years thanks to next generation gene sequencing (NGS) techniques which have made it possible to highlight unknown genetic variants of Alport syndrome. The family studied by us presents concomitant heterozygous alterations of the COL4A3 genes (c.1029+5G>A with MAF 0 and c.3211-7A>G with MAF 1:100000), heterozygous alterations of the MTHFR gene (both C677T and A1298C) and homozygous alteration of the PAI-1 gene. While the variant c.3211-7A>G, as shown by genetic databases (ClinVar), appears to be benign, the intronic variant c.1029+5G>A (caused by exon skipping) can be classified as pathogenic due to its characteristics and the fact that it co-segregates with the phenotype within the family. The histological data, in one of the sisters, highlighted the presence of a discrete global glomerular sclerosis and the ultrastructural investigation a thinning of the glomerular basement membrane. New mutational variants of the COL4A3 gene may play a role as risk variants for the development of chronic kidney disease.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natale Gaspare De Santo, Carmela Bisaccia, Luca Salvatore De Santo
Gout is a common, complex, systemic and well-studied form of chronic inflammatory arthritis due to deposition of sodium monourate crystals in peripheral joints and periarticular tissues driven by hyperuricemia. Gout is the oldest recorded inflammatory arthritis to affect humankind, with roots stretching back to 2640 BCE. To establish the timeline of gout from the Corpus Hippocraticum to the Renaissance, this study focuses on Galen (129-c.215 CE). A princeps English edition of Galen's works is still lacking; therefore, this paper provides a translation of the paragraph on gout from the Latin edition [12] by Carolus Gottlob Kühn (Leipzig, 1821-1833). Galen departs from Hippocrates and displays a vast knowledge of pathogenesis, symptomatology, clinical course, differential diagnosis, therapeutic skills and prognostication. In Galen's view, gout is due to fluid overflow that infiltrates nerves and causes pain. Overflowing fluid may be blood, phlegm, or a mixture of bile, blood, and phlegm. The prevailing humor is crude, mucous, and thick, and by residing in the joint, causes tophi. The nature of infiltrating humor can be diagnosed through color of the joint, symptoms, effects of heat and cold, effects of drugs, and information related to age, diet, quantity and quality of exercise, attitude towards baths of the patient. Treatment, according to Galen, required immediate bloodletting by venesection at the elbow, which could be repeated. Purges, enemas, and/or emetics are additionally needed to evacuate the humor(s). Poultices played a role draining the humor(s) as well as for their emollient-softening properties.
痛风是一种常见的、复杂的、全身性的、研究充分的慢性炎症性关节炎形式,它是由高尿酸血症驱动的单酸钠晶体在周围关节和关节周围组织沉积引起的。痛风是影响人类的最古老的炎症性关节炎,其根源可以追溯到公元前2640年。为了确定从希波克拉底文集到文艺复兴时期痛风的时间线,本研究将重点放在盖伦(129-c.215)身上CE)。盖伦著作的主要英文版至今仍未出版;因此,本文提供了Carolus Gottlob k hn (Leipzig, 1821-1833)的拉丁版[12]中关于痛风的段落的翻译。盖伦从希波克拉底出发,在发病机理、症状学、临床过程、鉴别诊断、治疗技巧和预后方面展现了丰富的知识。在盖伦看来,痛风是由于液体溢出渗入神经而引起疼痛。溢液可能是血、痰,也可能是胆汁、血和痰的混合物。主要的幽默是粗糙的、黏液状的、粘稠的,由于存在于关节中,引起痛风。浸润性幽默的性质可以通过关节的颜色、症状、冷热作用、药物作用以及患者的年龄、饮食、运动的数量和质量、洗澡的态度等信息来诊断。根据盖伦的说法,治疗需要立即在肘部进行静脉切除放血,这可以重复。此外,还需要清除、灌肠和/或催吐剂来排出幽默。膏药起到了排空幽默的作用,同时也起到了润肤软化的作用。
{"title":"[Gout From the Corpus Hippocraticum to the Renaissance: The Role of Galen].","authors":"Natale Gaspare De Santo, Carmela Bisaccia, Luca Salvatore De Santo","doi":"10.69097/42-02-2025-14","DOIUrl":"https://doi.org/10.69097/42-02-2025-14","url":null,"abstract":"<p><p>Gout is a common, complex, systemic and well-studied form of chronic inflammatory arthritis due to deposition of sodium monourate crystals in peripheral joints and periarticular tissues driven by hyperuricemia. Gout is the oldest recorded inflammatory arthritis to affect humankind, with roots stretching back to 2640 BCE. To establish the timeline of gout from the Corpus Hippocraticum to the Renaissance, this study focuses on Galen (129-c.215 CE). A princeps English edition of Galen's works is still lacking; therefore, this paper provides a translation of the paragraph on gout from the Latin edition [12] by Carolus Gottlob Kühn (Leipzig, 1821-1833). Galen departs from Hippocrates and displays a vast knowledge of pathogenesis, symptomatology, clinical course, differential diagnosis, therapeutic skills and prognostication. In Galen's view, gout is due to fluid overflow that infiltrates nerves and causes pain. Overflowing fluid may be blood, phlegm, or a mixture of bile, blood, and phlegm. The prevailing humor is crude, mucous, and thick, and by residing in the joint, causes tophi. The nature of infiltrating humor can be diagnosed through color of the joint, symptoms, effects of heat and cold, effects of drugs, and information related to age, diet, quantity and quality of exercise, attitude towards baths of the patient. Treatment, according to Galen, required immediate bloodletting by venesection at the elbow, which could be repeated. Purges, enemas, and/or emetics are additionally needed to evacuate the humor(s). Poultices played a role draining the humor(s) as well as for their emollient-softening properties.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}